Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated consistent efficacy and safety regardless of diuretic type or dose and reduced overall diuretic requirements in patients ...

A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The Texas Heart Institute and led by his research and residency mentor, University of Texas Southwestern ...

The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than ...

High blood pressure, also known as hypertension, is a common health issue, affecting nearly half of adults in the United States (48%). When an individual is diagnosed with high blood pressure, one of ...

Please provide your email address to receive an email when new articles are posted on . Researchers found a notable interaction based on patients' prior history of kidney stones. Hypokalemia was more ...

What Is Enbumyst, and Why Does It Matter? Enbumyst is a new nasal spray form of bumetanide (first approved by the FDA in 1983). It is a type of medicine called a loop diuretic (also known as a “water ...

AUSTIN, Texas -- The diuretic spironolactone stopped the progression of atherosclerosis in people with type 2 diabetes and chronic kidney disease (CKD), according to the MAGMA trial. Among 79 patients ...

Diuretic doses in patients with heart failure could be down-titrated effectively using a simple, noninvasive, home-based monitoring system, according to findings from a pilot study presented at the ...